Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Markets

Wellgistics Health, Inc. (NASDAQ: WGRX), a holding company for various strategic businesses centered around healthcare technology and pharmaceutical services, has entered into an agreement with Tollo Health, LLC to market Tollo's proprietary suite of novel medical food products. This strategic partnership aims to address unmet medical needs in the multi-billion dollar GLP-1 and Long COVID markets.

Tollo Health's medical foods target muscle loss and gut discomfort associated with GLP-1 drug use, as well as various Long COVID symptoms. The first marketed product, Galectovid™, is a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections. By partnering with Tollo Health, Wellgistics Health seeks to provide patients with dietary support to get the most out of prescription drugs and other treatment modalities used by their physicians to manage complex chronic conditions.

The GLP-1 drug market is currently valued at $46.7 billion and is expected to grow to $322 billion by 2034. According to the U.S. Census Bureau, around 16 million working-age Americans (aged 18 to 65) have Long COVID, which represents lost wages of at least $170 billion annually. Tollo believes that its medical foods represent an immediately available solution, supported by their Generally Recognized As Safe (GRAS) safety profile and efficacy data referenced from independent peer-reviewed studies on key ingredients.



Wellgistics Health's expansion into medical foods is expected to directly impact its pharmacy clients and support physicians and the patients they serve. By marketing Tollo's medical foods, Wellgistics aims to help manage the side effects of GLP-1 drugs and the devastating impacts of Long COVID, as there are no approved prescription treatment options currently available. The partnership also creates a cross-selling strategy that could help grow Wellgistics' customer base and position them as the key supplier for healthcare professionals in the GLP-1 and Long COVID markets.

In conclusion, Wellgistics Health's partnership with Tollo Health addresses unmet medical needs in the GLP-1 and Long COVID markets by introducing novel medical food products. This strategic move aligns with Wellgistics' long-term growth strategy and positions the company to capitalize on the growing demand for solutions to manage the side effects and symptoms of these conditions. As the market for GLP-1 drugs and Long COVID continues to expand, Wellgistics Health is well-positioned to capture a significant share of this lucrative market.